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uDetection of intracardiac masses has long been recog-
nized as a strength of transthoracic 2-dimensional
echocardiography (TTE) (1). The sensitivity and
specificity of TTE for detection of left ventricular
thrombus (LVT) was established by comparison of
“adequate” TTEs on highly select patients with sur-
gical or post-mortem findings (2–4). It quickly became
and remains the preferred method to detect LVT.
See page 702
In this issue of iJACC, Weinsaft et al. (5), report
performance characteristics of clinical TTE for
detection of LVT in a consecutive series of patients
with left ventricular dysfunction from a dedicated
cardiac magnetic resonance (CMR) registry. A
research protocol delayed-enhancement CMR
(DE-CMR), shown to have high sensitivity and
specificity for detecting LVT (6), was performed to
evaluate for LVT and compared with a “clinical
TTE” performed within 1 week of registry DE-
CMR. For this and another study comparing CMR
and TTE for detecting LVT (7), all CMR patients
were included regardless of TTE quality although
the selection criteria were not clearly described. The
prevalence of LVT in the article by Weinsaft et al.
(5) DE-CMR was 10% and TTE 12% but there
was substantial “discordance” between the 2 tech-
niques. Clinical/pathology endpoints at 6-month
follow-up were higher in patients with LVT de-
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the Cardiology Division, Department of Internal Medicine, Hen-
nepin County Medical Center and the University of Minnesota, Minne-
apolis, Minnesota. †Oliver MS, Young JT. T’aint What You Do (It’s the
Way That You Do It). Available at: http://www.youtube.com/watch?vt
X8fCXNTCWig#t1m08s. Accessed April 14, 2011. The authors have
reported that they have no relationships to disclose.ected by DE-CMR, which the investigators feel
support DE-CMR as an appropriate reference
tandard.” The sensitivity, specificity, and predictive
alue of clinical TTE for detection of LVT com-
ared with the DE-CMR reference standard are
eported noting that use of an echocardiographic
ontrast agent, a method reported to increase the
redictive value of TTE for LVT detection (8–10)
as infrequent. As the investigators stress, this
hould not be considered a direct comparison of the
methods. An “intent to image” comparison of the
imaging modalities in a general population where
hose with “inadequate” TTEs and “contraindi-
ated” DE-CMR were excluded may show different
esults. The predictive value of TTE was higher
hen the clinical indication was to evaluate for LVT
nd the quality of the TTE high. Smaller “intracavi-
ary” and mural LVT, regardless of size, were more
ommonly detected by DE-CMR than by clinical
TE. The investigators conclude that routine clinical
cho can yield misleading results concerning detection
f LVT (5).
The dismal performance of routine TTE in
ontrast to DE-CMR raises concern regarding the
eliability of TTE for detecting LVT. Original
eports of the reliability of TTE for detecting LVT
ere from adequate TTE studies of high-risk pa-
ients, focused on detecting LVT (2–4). Inadequate
r inconclusive TTEs have been reported in a high
ercentage of patients being evaluated for LVT
9,11) when echo contrast was not used. In part,
his may explain the poor performance of TTE in
he investigators’ report. Nevertheless, the observa-
ions point out potential limitations of routine
linical TTE for detecting LVT, particularly when
he indication is not specific and echo contrast is
sed infrequently. These results send clear messages
o clinicians and echocardiographers.
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714First is the importance of the specific indication for
TTE. If LVTwas the indication, TTE’s sensitivity for
detecting LVT nearly doubled in the study by Wein-
saft et al. (5). If the indication is vague, TTE becomes
a “screening” tool and its performance is reduced. The
second relates to the technical performance of TTE.
Useful techniques for detection of LVT and avoidance
of false positives by TTE include attention to the LV
apex (the most common site for LVT) where multiple
depths of field, high transducer frequency, nonstan-
dard acoustic windows, varying gain and sensitivity
settings and verification on more than view are im-
portant (3,12). Previous and serial TTEs can also be
valuable in understanding the anatomy of the left
ventricle and correctly identifying normal structures.
As the investigators stress, second harmonic imaging
with echo contrast is particularly helpful in improving
detection of LVT (8–10).
A prospective comparison of TTEs and DE-
CMRs from multiple centers for detection of LVT
would be welcomed but will likely show that both are
reliable methods if performed well in selected popu-
lations. Ella Fitzgerald’s popular 1939 recording says it
well “T’aint what you do (it’s the way that you do it)” and
applies to performance of TTE, DE-CMR, and com-
parisons of diagnostic tests.
As with any diagnostic test, clearly defining the
clinical indication enhances its predictive value. High-
risk clinical settings for LVT include: 1) stroke,
transient ischemic attack, or systemic embolism;
2) recent myocardial infarction—particularly the first
3 months following anterior infarction; 3) left ventric-
ular aneurysm; and 4) decreased left ventricular sys-EO, et al. Comparison of indium-111 Coll Cardiol Img 2should include the basic imaging described here in-
cluding echo contrast unless findings are unequivocal.
The use of echo contrast is limited by cost and was
undoubtedly affected by the U.S. Food and Drug
Administration’s “black box” warning (13), which may
have inadvertently limited the clinical use of a valuable
adjunct to TTE. The frequency of serious adverse
events reported for perflutren (an echo contrast agent)
should allay any safety concerns (14–16). Support by
professional societies for echo contrast to improve
overall image quality and accuracy of interpretation
seems appropriate.
The observations by Weinsaft et al. (5) should
nfluence clinical practice and guide further investiga-
ion. When detection of LVT would influence treat-
ent, clinicians should not rely on suboptimal TTEs;
nother diagnostic test such as DE-CMR or CT scan
17) should be performed. The natural history of LVT
ith contemporary treatment of acute myocardial
nfarction and congestive heart failure is variably re-
orted (18–21) and the embolic potential of LVT in
arious clinical settings continues to be unclear as is
he efficacy of anticoagulation for primary prevention
f embolism, its duration, and endpoint (18,22,23).
oth TTE and DE-CMR could play complimentary
oles in further defining both the incidence and
mbolic potential of LVT.
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